Therapeutic cannabinoids in multiple sclerosis: immunomodulation revisited

Constantinescu, Cris S.; Gershkovich, Pavel

Abstract

Cannabinoids are compounds with pleiotropic properties that act on the cannabinoid receptors, CB1 and CB2, and are divided into endocannabinoids, the endogenous ligands of these receptors, synthetic cannabinoids and phytocannabinoids. The latter are derived from the plant Cannabis sativa. The therapeutic and psychoactive properties of this plant have been observed and used for centuries. Of the over 60 compounds that are unique to Cannabis sativa, the substances that have been attributed the greatest therapeutic potential are Δ9‐ tetrahydrocannabinol (THC) and cannabidiol (CBD), both of which, used alone or combined with each other, have become approved drugs.

Citation

Constantinescu, C. S., & Gershkovich, P. (2018). Therapeutic cannabinoids in multiple sclerosis: immunomodulation revisited. European Journal of Neurology, 25(7), 905-906. https://doi.org/10.1111/ene.13658

• Journal Article Type: Article
• Acceptance Date: Apr 5, 2018
• Online Publication Date: Apr 10, 2018
• Publication Date: Jul 1, 2018
• Deposit Date: Apr 9, 2018
• Publicly Available Date: Apr 11, 2019
• Journal: European Journal of Neurology
• Print ISSN: 1351-5101
• Electronic ISSN: 1468-1331
• Publisher: Wiley
• Peer Reviewed: Peer Reviewed
• Volume: 25
• Issue: 7
• Pages: 905-906
• DOI: https://doi.org/10.1111/ene.13658
• Public URL: https://nottingham-repository.worktribe.com/output/943329
• Publisher URL: https://onlinelibrary.wiley.com/doi/abs/10.1111/ene.13658
• Additional Information: This is the peer reviewed version of the following article, which has been published in final form at https://onlinelibrary.wiley.com/doi/abs/10.1111/ene.13658. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.
• Contract Date: Apr 9, 2018